Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OE amlodipine · 1 trial · 1 indication
An ambulatory blood pressure monitor (ABPM) fitted to upper arm was used for continuous recording of blood pressure over three 25-hour periods: Days -1 to 0 (Baseline), Days 6 to 7, \& Days 13 to 14. The ABPM recorded blood pressure every 20 minutes between 09:00 and 21:59 and every 30 minutes between 22:00 and 08:59. SBPday was calculated by averaging all of the systolic blood pressure measurements between the protocol-defined first \& last study measurements of the period that fell between 9:00 and 21:00; measurements during the first hour (white-coat window) were not included. Change in SBPday was calculated by subtracting the Baseline value from the end of study value (Day 13 to Day 14 period). If the Day 13 to Day 14 value was not available, the Day 6 to Day 7 value was used \[last observation carried forward (LOCF) method\]. A negative value for change in SBPday indicates a decrease in systolic blood pressure and a positive value indicates an increase.
| Arm | Type | Description |
|---|---|---|
| Amlodipine+Celecoxib | EXPERIMENTAL | OE 10 mg amlodipine besylate tablet + OE 200 mg celecoxib capsule qd for 14 days |
| Amlodipine+Placebo | ACTIVE_COMPARATOR | OE 10 mg amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days |
| Placebo+Placebo | SHAM_COMPARATOR | Matched placebo for OE amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days |
| Name | Type | Description |
|---|---|---|
| OE 10 mg amlodipine besylate tablet | DRUG | - |
| OE 200 mg celecoxib capsule | DRUG | - |
| Matched placebo for OE amlodipine besylate tablet | DRUG | - |
| Matched placebo for OE celecoxib capsule | DRUG | - |
Inclusion Criteria: 1. Adult 40 to 75 years of age 2. Existing hypertension that is being treated using pharmacological therapy with a single agent that is not a calcium channel blocker 3. SBPday \> 135 and ≤ 169 mmHg and average daytime (9:00 to 21:00) ambulatory diastolic blood pressure (DBPday) ...
OE amlodipine is an investigational small molecule being developed for the treatment of hypertension. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with existing hypertension who require antihypertensive therapy.
OE amlodipine is being developed by Purple Biotech Ltd., a biopharmaceutical company listed on the stock exchange under the ticker symbol PPBT. The company is conducting clinical research on this investigational drug for the treatment of hypertension.
OE amlodipine is currently in Phase 3 clinical development for hypertension. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
OE amlodipine has one completed Phase 3 clinical trial, identified as NCT02979197. This randomized, double-blind, active-controlled study evaluated the effects of celecoxib on amlodipine in 105 subjects with existing hypertension requiring antihypertensives. The trial was conducted in the United Kingdom.
OE amlodipine is a formulation of amlodipine, a calcium channel blocker used to treat high blood pressure. The 'OE' designation may indicate a specific formulation or development program by Purple Biotech Ltd. The drug is being studied for hypertension, the same indication as standard amlodipine.